WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a global clinical research organization in the design, development, and management of complex clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies, announced today that it received a letter from Nasdaq Listing Qualifications on August 6, 2008 stating that solely as a result of the resignation of Paul J. Schmidt from Encorium’s Board of Directors, effective as of June 16, 2008, Encorium was not currently in compliance with Nasdaq’s independent director requirements as set forth in Marketplace Rule 4350.
